Name: ZYMEWORKS INC (ZYME) Stock
Brand: ZYMEWORKS INC
Rating: 7.5 (3 reviews)

ZYME Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Chartmill - Mentions: TAIT SSP CANG APLT ...

Let's take a look at the stocks that are in motion in today's session.

4 days ago - By: Chartmill - Mentions: JAZZ TAIT SSP CANG ...

The market is filled with gapping stocks in Monday's session.

2 days ago - By: Zacks Investment Research - Mentions: ALKS JAZZ CRMD

JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data

3 days ago - By: MarketNewsUpdates.com - Mentions: AVAI RXRX NTLA ANVS

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

3 days ago - By: Benzinga - Mentions: LGN AES HON REG ...

Alphabet To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday

3 days ago - By: Zymeworks Inc.

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

3 days ago - By: Zymeworks Inc.

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

3 days ago - By: Zymeworks Inc.

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

3 days ago - By: Zymeworks Inc.

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

4 days ago - By: Investor's Business Daily - Mentions: JAZZ

Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer

4 days ago - By: Chartmill - Mentions: TAIT SSP RPTX HKIT ...

These stocks are moving in today's pre-market session

4 days ago - By: Zymeworks Inc.

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

4 days ago - By: Zymeworks Inc.

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

10 days ago - By: Chartmill

Zymeworks Inc (NASDAQ:ZYME) Shows Strong Technical and Fundamental Momentum

14 days ago - By: Chartmill

Zymeworks Inc (NASDAQ:ZYME) Reports Mixed Q3 2025 Results with Narrower Loss but Revenue Miss

14 days ago - By: Zacks Investment Research - Mentions: IRD

Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates

14 days ago - By: Zymeworks Inc.

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

14 days ago - By: Zymeworks Inc.

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

15 days ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

17 days ago - By: Zacks Investment Research - Mentions: OBIO

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

22 days ago - By: Zacks Investment Research - Mentions: ADPT

Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

22 days ago - By: Zacks Investment Research

Zymeworks (ZYME) Upgraded to Strong Buy: Here's What You Should Know

24 days ago - By: Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

24 days ago - By: Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

a month ago - By: Zymeworks Inc.

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

a month ago - By: Zymeworks Inc.

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

a month ago - By: Zymeworks Inc.

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

a month ago - By: Zymeworks Inc.

ZYMEWORKS INC (ZYME) Stock News

ZYME Latest News, Press Relases and Analysis